Autoimmune Gastritis
Autoimmune gastritis (AIG) is a persistent inflammatory condition characterized by the immune system's attack on the gastric parietal cells, which are responsible for producing stomach acid and intrinsic factors. As a renowned contract research organization (CRO) focusing on drug and therapy development, our company holds expertise in the field of autoimmune diseases, including AIG.
Introduction to Autoimmune Gastritis
Autoimmune gastritis (AIG) is a complex autoimmune disease that primarily affects the gastric mucosa. It is characterized by the presence of autoantibodies against gastric parietal cells, leading to chronic inflammation and gastric gland atrophy. This immune response results in the loss of acid-producing parietal cells and impaired gastric acid secretion. AIG prevalence varies among populations, with a higher incidence in individuals with coexisting autoimmune conditions such as type 1 diabetes, Hashimoto's thyroiditis, and pernicious anemia. The pathogenesis of AIG involves a combination of genetic predisposition, environmental factors (Helicobacter pylori infections), and immune dysregulation of the H+/K+-ATPase proton pump and intrinsic factor.
Fig.1 Histopathological analysis of autoimmune gastritis (a) and type-I gastric neuroendocrine tumor (b). (Rustgi S. D., et al., 2021)
Drug Discovery and Development for Autoimmune Gastritis
Correcting these deficiencies is essential to prevent anemia and neurological complications. In severe cases of AIG, immunosuppressive agents may be considered to modulate the autoimmune response. However, their use is limited due to potential side effects and the need for careful monitoring. Moreover, the development of locally acting anti-inflammatory agents is an area of active research in AIG therapy. These agents aim to target the gastric mucosa and reduce inflammation without suppressing the immune system.
Our company is dedicated to advancing drug and therapy development in the field of autoimmune gastritis. Through our comprehensive therapeutic development services, we aim to develop innovative therapies and personalized solutions for global pharmaceutical companies. Please click on the link below to learn more about our diverse therapeutic development platform.
Our Services
At our company, we offer a comprehensive range of services to support the diagnostics and therapeutic development of autoimmune gastritis. Our expertise and cutting-edge technologies enable us to provide accurate diagnostics, efficient preclinical research, and the development of novel therapeutic strategies. We conduct rigorous preclinical research to assess the safety and efficacy of novel drug candidates, including immunomodulatory agents and locally acting anti-inflammatory therapies.
Spontaneous C3H/He Models
At our company, we can develop a C3H/He mouse line with a high incidence of spontaneous autoimmune gastritis. This model closely mimics the human condition, displaying histological evidence of gastritis and the presence of circulating autoantibodies to gastric parietal cells and the gastric H/K-ATPase.
Induced Autoimmune Gastritis
Induced autoimmune gastritis models allow researchers to study the disease under controlled conditions by manipulating specific factors. We offer various methods to induce autoimmune gastritis in animal models, including neonatal thymectomy, immunization with specific antigens, or genetic modifications.
Cell-Based Models
Cell-based models play a crucial role in in vitro research. At our company, we offer comprehensive services for developing and utilizing cell-based models to study autoimmune gastritis. By isolating and culturing relevant cell types, such as gastric epithelial cells, immune cells, and fibroblasts, we recreate the microenvironment essential for studying the disease.
Organoid Models
Using patient-derived or animal model stem cells, we generate gastric organoids that recapitulate the cellular diversity and architecture of the gastric epithelium. These organoids contain functional gastric parietal cells, allowing for the investigation of autoimmune gastritis-specific processes, such as autoantibody-mediated damage and inflammatory responses.
Why Choose Us?
Our expertise in preclinical research ensures robust data generation and supports the advancement of therapeutic interventions. In addition to the aforementioned services and models, we also provide customized solutions and develop disease models that cater specifically to your unique needs. If our services have piqued your interest, please do not hesitate to contact us.
References
- Rustgi S. D., et al. "Autoimmune gastritis, with or without pernicious anemia: epidemiology, risk factors, and clinical management." Therapeutic advances in gastroenterology 14 (2021): 17562848211038771.
- Orgler E., et al. "Autoimmune gastritis: update and new perspectives in therapeutic management." Current Treatment Options in Gastroenterology 21.1 (2023): 64-77.